COMMUNIQUÉS West-GlobeNewswire

PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline
26/08/2025
PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline Pre-submission file completed with [...]
PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire
26/08/2025
PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire Dossier de pré- [...]
Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira
26/08/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira and lowering of minimum acceptance condition to 75%
26/08/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development
26/08/2025
David Schilansky transitions to CEO, bringing 25 years of company-building, scaling and financing to advance Ariceum’s pipeline of novel radiotherapeutics Initiation of Phase 1/2 SANTANA-225 study of 225Ac-SSO110 in [...]
Nicox Announces Shareholder Q&A Webpage Available
26/08/2025
Press Release Nicox Announces Shareholder Q&A Webpage Available August 26, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology [...]
Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet
26/08/2025
Communiqué de presse Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet 26 août 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, [...]
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
26/08/2025
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio [...]
Synergy CHC Corp. Announces Pricing of $4.375 Million Public Offering
26/08/2025
WESTBROOK, Maine, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (Nasdaq: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced the pricing of an underwritten public [...]
Hydreight Achieves 33% YoY H1 Revenue Growth, Records 3rd Consecutive Quarter of Profitability, and Strengthens Performance Across Verticals
26/08/2025
“We had a great first 6 months, with 33% year-over-year growth. We have also exceeded our internal metrics across all verticals in the first seven months of the year, reinforcing the strength of our strategy. A key [...]
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
25/08/2025
PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the [...]
Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway
25/08/2025
- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, [...]
Memgen Announces First Patient Dosed in Phase 1 Combination Cohort of MEM-288 Plus Docetaxel in Advanced Non–Small Cell Lung Cancer
25/08/2025
Study designed to assess safety and antitumor activity; data intended to inform a planned randomized Phase 2 study TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Memgen, Inc., a clinical-stage biotechnology company [...]
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
25/08/2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients [...]
Option Care Health To Participate in Upcoming Investor Conferences
25/08/2025
BANNOCKBURN, Ill., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]
RxSight, Inc. to Present at the Morgan Stanley Healthcare Conference
25/08/2025
ALISO VIEJO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
OrthoPediatrics Corp. Announces the Appointment of Kelly Fischer to its Board of Directors
25/08/2025
WARSAW, Ind., Aug. 25, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
25/08/2025
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, [...]
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
25/08/2025
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today [...]

Pages